Abstract
Diabetes is a major cause of mortality and morbidity due to the long term microvascular complications of this disease. There is now convincing evidence to show that genetic factors together with elevated blood glucose play an important role in the susceptibility to diabetic nephropathy as well as retinopathy. The polyol pathway is thought to play an important role in the pathogenesis of diabetic microvascular complications. Aldose reductase is the first and rate-limiting enzyme of the polyol pathway. Polymorphisms in the promoter region as well as elsewhere in the gene have been associated with susceptibility to nephropathy, retinopathy as well as diabetic neuropathy. These associations have been replicated in patients with either type 1 or type 2 diabetes mellitus as well as across ethnic groups. These polymorphisms in the promoter region are also associated with expression of the gene. Although clinical trials using inhibitors of aldose reductase to treat diabetic microvascular complications have largely been unsuccessful, the identification of the susceptibility genes may help in the design of future drug regimens.
Keywords: diabetic nephropathy, retinopathy, neuropathy, diabetes, aldose reductase, polyol pathway, genetics
Current Medicinal Chemistry
Title: Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Volume: 10 Issue: 15
Author(s): A. G. Demaine
Affiliation:
Keywords: diabetic nephropathy, retinopathy, neuropathy, diabetes, aldose reductase, polyol pathway, genetics
Abstract: Diabetes is a major cause of mortality and morbidity due to the long term microvascular complications of this disease. There is now convincing evidence to show that genetic factors together with elevated blood glucose play an important role in the susceptibility to diabetic nephropathy as well as retinopathy. The polyol pathway is thought to play an important role in the pathogenesis of diabetic microvascular complications. Aldose reductase is the first and rate-limiting enzyme of the polyol pathway. Polymorphisms in the promoter region as well as elsewhere in the gene have been associated with susceptibility to nephropathy, retinopathy as well as diabetic neuropathy. These associations have been replicated in patients with either type 1 or type 2 diabetes mellitus as well as across ethnic groups. These polymorphisms in the promoter region are also associated with expression of the gene. Although clinical trials using inhibitors of aldose reductase to treat diabetic microvascular complications have largely been unsuccessful, the identification of the susceptibility genes may help in the design of future drug regimens.
Export Options
About this article
Cite this article as:
Demaine G. A., Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications, Current Medicinal Chemistry 2003; 10 (15) . https://dx.doi.org/10.2174/0929867033457359
DOI https://dx.doi.org/10.2174/0929867033457359 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry Zinc and Type 2 Diabetes Mellitus with Periodontitis- A Systematic Review
Current Diabetes Reviews Genetic Analysis of Aldose Reductase in Diabetic Complications
Current Medicinal Chemistry Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives
Current Diabetes Reviews P2X Receptors and Diabetes
Current Medicinal Chemistry Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews Bone Disease in Diabetes
Current Diabetes Reviews Antioxidant Effects of Glutathione and IGF in a Hyperglycaemic Cell Culture Model of Fibroblasts: Some Actions of Advanced Glycaemic end Products (AGE) and Nicotine
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model
Current Bioactive Compounds Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)